This latest evolution of HVLD aims to achieve a high level of closed container integrity (CCI) assurance across the entire range of parenteral products.
While there are a certain amount of commonalities in regulations in each country, there are differences which necessitate care from global manufacturers when distributing products.
Container closure integrity defects might be highly hazardous if not detected prior to administration. In fact, they can be even more dangerous than particles contained in pharmaceutical liquids.
The generics market has taken off in recent years due to numerous patent expirations for brand-name companies. In light of this, pharmaceutical manufacturers, insurance companies and consumers, in search of significant cost savings, have turned towards the generics industry.
Organizations that consistently develop and launch new products efficiently in an environment of increasing regulatory scrutiny, successfully manage regulatory risk. By Mike Kuehne, ACSYS, Inc.
Implementing a vision inspection solution to monitor the quality and security of your personal care product is an effective quality control method that allows processes to reach maximum throughput and productivity. By Wayne Eide
For those who haven’t checked their watch lately we’d like to remind you there are only two years until California’s serialization mandates take effect. By John DiPalo, Chief Operations Officer